Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.540
+0.010 (0.40%)
May 7, 2026, 12:16 PM EDT - Market open
Spero Therapeutics Revenue
In the year 2025, Spero Therapeutics had annual revenue of $66.80M with 39.24% growth. Spero Therapeutics had revenue of $41.30M in the quarter ending December 31, 2025, with 174.51% growth.
Revenue (ttm)
$66.80M
Revenue Growth
+39.24%
P/S Ratio
2.19
Revenue / Employee
$2,672,080
Employees
25
Market Cap
147.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 66.80M | 18.83M | 39.24% |
| Dec 31, 2024 | 47.98M | -55.80M | -53.77% |
| Dec 31, 2023 | 103.78M | 50.27M | 93.95% |
| Dec 31, 2022 | 53.51M | 35.25M | 193.10% |
| Dec 31, 2021 | 18.26M | 8.93M | 95.67% |
| Dec 31, 2020 | 9.33M | -8.82M | -48.59% |
| Dec 31, 2019 | 18.15M | 14.18M | 357.56% |
| Dec 31, 2018 | 3.97M | 1.99M | 100.40% |
| Dec 31, 2017 | 1.98M | 1.64M | 490.75% |
| Dec 31, 2016 | 335.00K | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innate Pharma | 10.57M |
| Alpha Cognition | 10.22M |
| Equillium | 4.39M |
| Alps Group | 3.74M |
| Connect Biopharma Holdings | 64.00K |
| InflaRx | 34.44K |
SPRO News
- 1 day ago - Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - GlobeNewsWire
- 5 weeks ago - Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 7 weeks ago - Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 - GlobeNewsWire
- 4 months ago - Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis - GlobeNewsWire
- 5 months ago - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 months ago - Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 6 months ago - Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 - GlobeNewsWire
- 7 months ago - PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) - GlobeNewsWire